Kinase inhibitor

This page covers all Kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Cyclin-dependent kinases 4 and 6 (CDK4/CDK6), Cyclin-dependent kinase 4, Vascular endothelial growth factor receptor 2.

Targets

Cyclin-dependent kinases 4 and 6 (CDK4/CDK6) · Cyclin-dependent kinase 4 · Vascular endothelial growth factor receptor 2 · Receptor-type tyrosine-protein kinase FLT3 · Serine/threonine-protein kinase B-raf · ALK tyrosine kinase receptor · Tyrosine-protein kinase ABL1 · Bifunctional epoxide hydrolase 2 · Hepatocyte growth factor receptor · Dual specificity mitogen-activated protein kinase kinase 1

Marketed (21)

• Verzenio · Eli Lilly · Oncology · 3700
  Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.
• Kisqali · Novartis · Oncology · 3600
  Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide.
• Cometriq · Exelixis · Oncology · 2200
  Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.
• Ofev · Boehringer Ingelheim · Oncology · 2000
  Ofev works by blocking enzymes that promote fibrosis and tumor growth.
• Tafinlar · Novartis · Oncology · 1675
  Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth.
• Alecensa · Hoffmann-La Roche · Oncology · 700
  Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
• Bosulif · Pfizer · Oncology · 611
  Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells.
• Bosulif · Pfizer · Oncology · 611
  Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation.
• Stivarga · Bayer · Oncology · 400
  Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis.
• Tabrecta · Novartis Pharm · Oncology · 200
  Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.
• Cotellic · Roche · Oncology · 200
  Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells.
• Aliqopa · Bayer · Oncology
• Cometriq · Exelixis Inc · Oncology
  Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis.
• Litfulo · Pfizer · Immunology
  Ritlecitinib irreversibly inhibits JAK3 and TEC kinase family by blocking ATP binding site.
• Torisel · Pfizer · Oncology
  Torisel works by blocking the mTOR protein, which is involved in cell growth and division.
• Mekinist · Novartis · Oncology
  Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
• Tykerb · Novartis · Oncology
  Tykerb works by blocking the epidermal growth factor receptor, a protein that promotes cancer cell growth.
• OFEV® · Boehringer Ingelheim · Oncology
• Exkivity · Takeda · Oncology
• Gleevec · Novartis · Oncology
  Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation.
• Tarceva · Osi Pharms · Oncology
  Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow.

Phase 3 pipeline (1)

• PLB1001 · Beijing Pearl Biotechnology Limited Liability Company · Oncology
  PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.